ALVO
Alvotech

216
Mkt Cap
$1.52B
Volume
53,148.00
52W High
$13.70
52W Low
$4.81
PE Ratio
23.96
ALVO Fundamentals
Price
$5.03
Prev Close
$7.65
Open
$5.81
50D MA
$8.15
Beta
0.55
Avg. Volume
344,339.65
EPS (Annual)
-$0.8654
P/B
-8.76
Rev/Employee
$474,498.06
Loading...
Loading...
News
all
press releases
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
Zacks·8d ago
News Placeholder
More News
News Placeholder
Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength?
Cartesian Therapeutics, Inc. (RNAC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·14d ago
News Placeholder
Wall Street Analysts See a 105.88% Upside in Alvotech (ALVO): Can the Stock Really Move This High?
The mean of analysts' price targets for Alvotech (ALVO) points to a 105.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·20d ago
News Placeholder
Voyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock?
Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·26d ago
News Placeholder
Here's How Alvotech is Expanding its Portfolio Beyond Immunology
ALVO accelerates growth with soaring revenues and new biosimilars in ophthalmology, oncology and neurology via global alliances.
Zacks·1mo ago
News Placeholder
Alvotech (ALVO) Surges 8.6%: Is This an Indication of Further Gains?
Alvotech (ALVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·1mo ago
News Placeholder
Alvotech vs. Teva Pharma: Which Generic Drugmaker is the Better Play?
ALVO's partnership-driven model fuels surging biosimilar revenues, while TEVA leans on scale but faces debt and competitive pressures.
Zacks·1mo ago
News Placeholder
Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth
Alvotech's partnership-led strategy drives soaring biosimilar revenues, fresh approvals and a diversified pipeline across key therapies.
Zacks·2mo ago
News Placeholder
ALVO Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?
Alvotech trades near a 52-week low after a 38% drop in 2025, but soaring revenues and new biosimilar approvals highlight its growth path.
Zacks·2mo ago
News Placeholder
Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus
KOD's Q2 loss widens as it ramps up clinical studies for three key eye disease treatments with pivotal data readouts planned.
Zacks·3mo ago

Latest ALVO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.